



This work is licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/)

The Costs Of Psychosis And The Rationale For Early Intervention

Cleland Phillips

Abstract

There is often a delay of months or years between the onset of psychotic symptoms and the initiation of appropriate treatment. Early intervention is required to mitigate the negative consequences of prolonged periods of untreated symptoms. Phase-specific medicines are associated with improved outcomes, at least in the near future. Massive economic and societal expenses complement the terrible personal and family repercussions. Multiple studies have examined the long-term outcomes for schizophrenia patients experiencing their first episode. After five years, at least half of patients still have moderate-to-severe functional and/or social. Early psychosis may be a "critical period" for determining a patient's long-term prognosis, and course-influencing variables may provide a large treatment window of opportunity. One of the few ways to improve long-term outcomes is by reducing the time to treatment success. Typically, psychosis occurs in late adolescence or early adulthood. Patients with psychosis are more susceptible to anxiety problems, depression, aggression, drug addiction, and suicide. Early management has been associated with enhanced functional result, decreased recurrence rates, enhanced treatment adherence, and increased patient satisfaction.

Keywords: Early Intervention, Psychosis, Schizophrenia

Cleland Phillips: Advisor at Psychosis Int.

Introduction

To lessen the detrimental effects of protracted durations of untreated symptoms on a person's social and private life, early intervention is warranted. In addition, phase-specific therapies are linked to better results, at particular in the near run. To determine the ideal length of these programs, further study is required. There is often a lag of months or years between the development of psychotic manifestations and the beginning of suitable therapy, according to several research. The DUP, or Duration of Untreated Psychosis, refers to this interval [1].

A shorter length of undiagnosed psychosis is linked to an improved therapy response and enhances the probability of a successful recovery [2]–[4], therefore treating psychosis as soon as symptoms occur is crucial. Impoverished clinical and operational healing may be the outcome of a protracted wait before receiving therapy [5]–[7].

The first 5 years after commencement seem to be crucial since this is when the symptoms are most amenable to therapy. Moreover, if left unaddressed for a long period, psychosis may have a negative influence on a person in many aspects of their life [8]–[11]. Psychosis may have a significant negative impact on one's capacity to think, feel, do well in school or at work, and have fulfilling connections with families and friends. Other issues may develop, including social isolation, drug

use or engagement with the legal system, despair or other psychiatric problems, and even suicide [12]. Early intervention aims to reduce the emergence of these extra issues

People who are suffering psychotic may be in great discomfort and take risks with others or themselves. Early intervention shortens the period of time when someone is in pain or at danger of hurting themselves or other people. Teens and young adults' growth as they become autonomous, define their values, pursue careers, develop sexually and socially, etc., is severely hampered by psychosis. Early assistance helps children to resume their developmental trajectory.

The costs of psychosis

Psychotic disorders are a significant public health concern. When experiencing a psychotic episode, a person is in great discomfort and may behave in a way that is harmful to them or others. The strain brought on by psychosis is heavy. When it first appears in late adolescence, it seriously impairs a person's capacity to complete developmental activities. The development of one's own independence, identity, and beliefs may be endangered, as well as social, sexual, scholastic, and professional problems. Families are often under a lot of strain, and those who are suffering psychosis are more likely to develop additional psychopathologies, be victimized, live in poverty, and have more health issues. Huge economic and social costs accompany the devastating human consequences to people and families. Active psychosis was placed greater than paraplegia and visual impairment by the WHO as the third most incapacitating disorder. According to the WHO, schizophrenia and bipolar illness account for around 2 percentage points of all disability-adjusted lifespans, and lifespan is reduced by about 10 years. In western countries, 25% of women and 40% of men have a chronic, moderate-to-severe handicap. In the last 15 years, the development of atypical antipsychotics has coincided with a resurgence in interest for psychotherapy approaches like cognitive therapy as well as psychological and social processes like neuropsychological functioning. A new hope and greater interest in the start and initial phases of psychotic illnesses were engendered by these advances, together with the focus on the social care and research through into origins and path determinants of the main psychotic diseases. According to research, it often takes a long time before a young person with psychoses is assessed and treated [13]. Additionally, over time, these methods were often upsetting, alienating, and poorly implemented. The Primary Psychosis Prevention centers program founding of the International Early Psychosis Association are only two examples of the service delivery systems that have been developed and improved as a result of these occurrences together. Although these programs have conducted research to improve clinical practice using data, there are still numerous clinical care areas that need high-quality research support. Many organizations responded to perceived clinical needs with groundbreaking inventions, which are currently being developed and given empirical confirmation. As a result, the problem of caring for people early is still being worked on. It is quite difficult to argue with the reasoning behind choosing to intervene early in a disease rather than later. A review of the progression and results of psychotic diseases is necessary before going into further depth on the justification and objectives of early intervention [14]–[17].

The progression and results of psychotic illnesses

Schizophrenia, schizophreniform disease, schizoaffective condition, bipolar dysfunction, and severe depression with psychotic symptoms are the most often diagnosed conditions with psychosis. In many contexts across the globe, there is a rise in the use of drugs and other substances that might cause psychosis, and physicians are seeing more patients who report with such psychotic symptoms [18]–[22]. The majority of psychotic illnesses have a propensity to recur, with times of acute psychosis followed by phases of disruption, followed by periods of recovery, decline, and recurrence of florid psychosis. When the condition is thought of as having distinct stages, it is suggested that various tactics for evaluation and therapy are applicable at each stage. When all

psychotic diseases are taken into account, nearly half of sufferers were thought to have a positive result after 15 years, with schizophrenia accounting for 38% and the other psychoses for 55%. The percentage of recovered patients, however, drops to 16 percent for those who have schizophrenia and 36 percent for those who have other psychoses if more strict guidelines are used that isolate patients who had a treatment episode within the past 2 years, had shown no symptoms, and had a reasonable level of functioning.

Schizophrenia

Males with schizophrenia often first experience psychosis in their adolescents or early 20s; women often start having symptoms when they are many years older [23]–[27]. Schizophrenia typically begins in 39percent of men and 23percent of females before the age of 19. About 25% of cases of bipolar disorder begin at a somewhat later age than 20. Long-term results for schizophrenia patients having their initial episode have been the subject of several research. Typically, 20–30percent of individuals who have a first episode recover without any lasting symptoms. 20–42% of patients had poor symptomatic outcomes. At least half of patients still have moderate-to-severe functional and/or social impairment after five years. According to a five-year prospective research, 30% of patients had excellent outcomes, 14% had bad outcomes, and 56% had intermediate outcomes. About 27% of people had competitive jobs and strong social networks, while almost 40% had little or no symptoms. At five years, around half of the 20 percent of people who weren't using medication had successful results [28]. Other trials, however, have shown poorer results, with 50% of patients doing badly and fewer than 20% in recovery after 5 years. According to a recent epidemiological event research, after five years, 75% of first episode schizophrenia patients and almost 50% of people who had nonaffective psychoses were getting work disability payments. 39 percent of individuals without schizophrenia and 9 percent of those with schizophrenia were deemed to not need therapy. Data from trials with strong drug adherence rates, in contrast to these broad general response rates, provide a more positive picture of recovery. For instance, according to one research using injectable medicine, 85 percent of first period participants were symptomatically cured by one year, but according to another early psychosis program, fewer than 10% of patients still had positive symptoms at that time [29]–[33]. Poorer outcomes are more common in male patients with schizophrenia who also have cognitive impairment, lower premorbid functional levels, and less schooling [34]–[39]. Younger onsets, a history of substance misuse, a lack of close companions, and unpleasant symptoms are further indicators of worse long-term results. Compared to other psychotic diseases, schizophrenia is linked to worse functional outcomes and a slower rate of episode recovery.

Bipolar disorder

A classic relapsing-remitting mental condition is bipolar disorder. A 1.6% lifetime prevalence is average. People who have previously been admitted could expect to have episodes for 20% of their lifespan. About 10% of people will experience at least 10 episodes in their lifetime, and 90% of young people with mania will continue to experience relapses as adults. About 1/2 of bipolar incidents last anywhere from 2 and 7 months (median 3 months), with inter-episode periods getting shorter over time. 17% of patients with bipolar disorder had a poor general long-term result, according to a 15-year follow-up study. Good results were indicated by complete adherence to treatment, younger age at commencement, and male sex. Male sex and younger age at commencement, but not complete compliance, also indicated a positive psychological outcome [40]–[43]. These findings were not fully confirmed by other studies, which found that shorter hospital stays and larger start ages were related with faster times to syndromal and functional recovery. At 6 and 24 months, each, 84 percent and 97 percent of the participants in that research had achieved syndromal recovery, while only 30% and 3%, respectively, had achieved functional recovery. Another one-year follow-up of first episode patients revealed that, although only 35%

had symptomatic or functional recovery, 56% had experienced syndromal recovery. The discovery that a person's socioeconomic level predicts their likelihood of having better outcomes might imply that early treatment and behavioral therapy are protective since they allow for the well-established economic growth. Ultimately, compared to major depressive disorder without psychosis, major depressive disorder with psychosis had worse clinical and functional outcomes after five and ten years.

Premises and goals

It is clear from a study of the data on the progression and results of psychotic diseases that the prognosis is complex. The amount of time devoted with psychotic signs during the first several years is the greatest predictor for all psychotic illnesses, with the healthier the short trajectory, the improved the long-term prognosis. Numerous studies have identified significant delays in the onset of therapy for bipolar illness and initial episodes of psychosis. Long-term untreated psychosis (DUP) results have been linked to biological anomalies, relapses, and slower and less comprehensive recovery. Delay in intense psychosocial therapy (DIPT), a more recent idea, may also be linked to outcomes and associated with unpleasant symptoms. Early psychosis, when the majority of deterioration takes place, may be a "critical time" for deciding long-term fate. Due to the development and maximal capacity for positive change at this time, course-influencing biopsychosocial factors, including patient and family responses, may provide a significant therapeutic opportunity. It is complicated how long untreated psychosis lasts and how things turn out. Longer length does not always indicate a worse result, according to research. Shortening the time to successful treatment is one of a few methods to enhance long-term results, even if the association between length of undiagnosed psychosis and outcomes has to be clarified. Recently, there has been an increase in interest in treating psychotic diseases as soon as feasible in order to lessen suffering and risk now, as well as to enhance alike both short- as well as long-term prognoses. Psychosis usually begins in late teens or early adulthood, which significantly impairs the capacity of those who have the illness to cope with developmental problems. Parents and siblings suffer greatly, and family bonds deteriorate. Psychosis patients are more likely to suffer from anxiety disorders, sadness, violence, drug addiction, and suicide [44]–[48].

Effective early intervention aims to solve these issues by: • Providing age-appropriate assistance to lessen the impact on these people's lives and help them deal with developmental hurdles more effectively Reducing the suffering and potential consequences of psychotic activity; helping families; and being mindful of elements that can obstruct effective continuing treatment, such as the adverse effects of painful procedures; drug side effects; stigma; and other barriers to cooperation [44], [49], [50]. Treating linked issues including depression, violence, suicidal thoughts, drug misuse, cognitive decline, and anxiety disorders rather than believing that these traits are incidental effects.

There is growing evidence that early intervention is effective [51]–[53]. Involvement in early psychosis initiatives has been linked to improvements in functional outcome, reduced recurrence rates, improved treatment adherence, and higher patient satisfaction. It has also been linked to decreased DUP, hospitalization, police intervention in admissions, medication usage, and DUP [54], [55]. These programs also seem to be economical. Despite these successes, the creation and empirical verification of suitable treatments and service systems is still required to provide answers to many more issues. Research is required, for instance, to assess if intensive therapies enhance long-term outcomes or only postpone deterioration and how long they should persist. Early intervention may increase the bar for recovery even if it only delays deterioration since the patient's developmental demands are more complex.

References

- [1] R. M. G. Norman, S. W. Lewis, and M. Marshall, "Duration of untreated psychosis and its relationship to clinical outcome," *Br. J. Psychiatry Suppl.*, vol. 48, pp. s19-23, Aug. 2005.
- [2] J. Read and C. A. Ross, "Psychological trauma and psychosis: another reason why people diagnosed schizophrenic must be offered psychological therapies," *J. Am. Acad. Psychoanal. Dyn. Psychiatry*, vol. 31, no. 1, pp. 247–268, Spring 2003.
- [3] T. Calton, M. Ferriter, N. Huband, and H. Spandler, "A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed With Schizophrenia," *Schizophr. Bull.*, vol. 34, no. 1, pp. 181–192, Jun. 2007.
- [4] B. T. Mausbach, R. Moore, C. Bowie, V. Cardenas, and T. L. Patterson, "A Review of Instruments for Measuring Functional Recovery in Those Diagnosed With Psychosis," *Schizophr. Bull.*, vol. 35, no. 2, pp. 307–318, Nov. 2008.
- [5] S. P. Stefanatou Pentagiotissa, G. K. George Konstantakopoulos, E. G. Eleni Giannouli, S. V. Silia Vitoratou, and V. M. Venetsanos Mavreas, "The relationship between patients' needs and psychopathology in schizophrenia: Do patients and therapists agree?," *Eur. Psychiatry*, vol. 30, p. 1376, Mar. 2015.
- [6] R. M. Norman and A. K. Malla, "Duration of untreated psychosis: a critical examination of the concept and its importance," *Psychol. Med.*, vol. 31, no. 3, pp. 381–400, Apr. 2001.
- [7] B. Lloyd-Evans *et al.*, "Initiatives to shorten duration of untreated psychosis: systematic review," *Br. J. Psychiatry*, vol. 198, no. 4, pp. 256–263, Apr. 2011.
- [8] A. Malla and J. Payne, "First-episode psychosis: psychopathology, quality of life, and functional outcome," *Schizophr. Bull.*, vol. 31, no. 3, pp. 650–671, Jul. 2005.
- [9] I. Hasson-Ohayon, S. Kravetz, D. Roe, A. S. David, and M. Weiser, "Insight into psychosis and quality of life," *Compr. Psychiatry*, vol. 47, no. 4, pp. 265–269, Jul. 2006.
- [10] P. Fusar-Poli *et al.*, "Disorder, not just state of risk: meta-analysis of functioning and quality of life in people at high risk of psychosis," *Br. J. Psychiatry*, vol. 207, no. 3, pp. 198–206, Sep. 2015.
- [11] P. Stefanatou and E. Giannouli, "EPA-1030–The greek version of the camberwell assessment of need: psychometric properties and associations with quality of life and social disability in ...," *European*, 2014.
- [12] P. Stefanatou, E. Giannouli, Z. Antonopoulou, P. Tsellos, G. Vaslamatzis, and M. Typaldou, "The Concept of Time Perspective Within a Psychiatric Context," *Eur. Psychiatry*, vol. 33, no. S1, pp. S507–S508, Mar. 2016.
- [13] J. Edwards and P. D. McGorry, *Implementing early intervention in psychosis: A guide to establishing psychosis services*. CRC Press, 2002.
- [14] K. Kollias *et al.*, "The development of the Early Intervention in Psychosis (EIP) outpatient unit of Eginition University Hospital into an EIP Network," *Psychiatrike*, vol. 31, no. 2, pp. 177–182, Apr. 2020.
- [15] M. Marshall and J. Rathbone, "Early intervention for psychosis," *Schizophr. Bull.*, vol. 37, no. 6, pp. 1111–1114, Nov. 2011.
- [16] P. D. McGorry, "Early intervention in psychosis: obvious, effective, overdue," *J. Nerv. Ment. Dis.*, vol. 203, no. 5, pp. 310–318, May 2015.
- [17] E. Killackey and A. R. Yung, "Effectiveness of early intervention in psychosis," *Curr. Opin. Psychiatry*, vol. 20, no. 2, pp. 121–125, Mar. 2007.
- [18] P. R. Corlett, C. D. Frith, and P. C. Fletcher, "From drugs to deprivation: a Bayesian framework for understanding models of psychosis," *Psychopharmacology*, vol. 206, no. 4, pp. 515–530, Nov. 2009.
- [19] R. A. Hoppmann, J. G. Peden, and S. K. Ober, "Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction," *Arch. Intern. Med.*, vol. 151, no. 7, pp. 1309–1313, Jul. 1991.
- [20] H. Y. Meltzer, B. W. Massey, and M. Horiguchi, "Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia," *Curr. Pharm. Biotechnol.*, vol. 13, no. 8, pp. 1572–1586, Jun. 2012.

- [21] P. Stefanatou and G. Konstantakopoulos, "Patients' needs as an outcome measure in schizophrenia," *European*, 2016.
- [22] Gonzalez-Pinto, Vega, and Ibanez, "Impact of cannabis and other drugs on age at onset of psychosis," *The Journal of clinical*, 2008.
- [23] J. T. Kenny *et al.*, "Cognitive impairment in adolescents with schizophrenia," *Am. J. Psychiatry*, vol. 154, no. 11, pp. 1613–1615, Nov. 1997.
- [24] M. Davidson, A. Reichenberg, J. Rabinowitz, M. Weiser, Z. Kaplan, and M. Mark, "Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents," *Am. J. Psychiatry*, vol. 156, no. 9, pp. 1328–1335, Sep. 1999.
- [25] H. Stierlin, "Separating parents and adolescents: A perspective on running away, schizophrenia, and waywardness," vol. 204, 1974.
- [26] G. Konstantakopoulos, N. Ioannidi, C. Psarros, P. Patrikelis, P. Stefanatou, and E. Kravariti, "The impact of neurocognition on mentalizing in euthymic bipolar disorder versus schizophrenia," *Cogn. Neuropsychiatry*, vol. 25, no. 6, pp. 405–420, Nov. 2020.
- [27] C. Hollis, "Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity," *Am. J. Psychiatry*, vol. 157, no. 10, pp. 1652–1659, Oct. 2000.
- [28] E. Aylward, E. Walker, and B. Bettes, "Intelligence in schizophrenia: meta-analysis of the research," *Schizophr. Bull.*, vol. 10, no. 3, pp. 430–459, 1984.
- [29] M. Birchwood, P. McGorry, and H. Jackson, "Early intervention in schizophrenia," *Br. J. Psychiatry*, vol. 170, pp. 2–5, Jan. 1997.
- [30] M. Birchwood and F. Macmillan, "Early intervention in schizophrenia," *Aust. N. Z. J. Psychiatry*, vol. 27, no. 3, pp. 374–378, Sep. 1993.
- [31] I. R. Falloon, "Early intervention for first episodes of schizophrenia: a preliminary exploration," *Psychiatry*, vol. 55, no. 1, pp. 4–15, Feb. 1992.
- [32] A. Hatzimanolis *et al.*, "Familial and socioeconomic contributions to premorbid functioning in psychosis: Impact on age at onset and treatment response," *Eur. Psychiatry*, vol. 63, no. 1, p. e44, Apr. 2020.
- [33] A. K. Malla and R. M. G. Norman, "Early intervention in schizophrenia and related disorders: advantages and pitfalls," *Curr. Opin. Psychiatry*, vol. 15, no. 1, p. 17, Jan. 2002.
- [34] J. J. Rodríguez Solano and M. González de Chávez, "Premorbid adjustment and previous personality in schizophrenic patients," *Eur. J. Psychiat.*, vol. 19, no. 4, pp. 243–254, 2005.
- [35] S. Dimitrakopoulos, A. Hatzimanolis, P. Stefanatou, L.-A. Xenaki, and N. Stefanis, "S125. The role of dup, DUI and polygenic score for schizophrenia on cognition in Athens fep study sample," *Schizophr. Bull.*, vol. 46, no. Supplement_1, pp. S82–S83, May 2020.
- [36] K. A. Woodberry, A. J. Giuliano, and L. J. Seidman, "Premorbid IQ in schizophrenia: a meta-analytic review," *Am. J. Psychiatry*, vol. 165, no. 5, pp. 579–587, May 2008.
- [37] G. M. Khandaker, J. H. Barnett, I. R. White, and P. B. Jones, "A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia," *Schizophr. Res.*, vol. 132, no. 2–3, pp. 220–227, Nov. 2011.
- [38] M. S. Keshavan, V. A. Diwadkar, D. M. Montrose, R. Rajarethinam, and J. A. Sweeney, "Premorbid indicators and risk for schizophrenia: a selective review and update," *Schizophr. Res.*, vol. 79, no. 1, pp. 45–57, Nov. 2005.
- [39] H. E. Cannon-Spoor, S. G. Potkin, and R. J. Wyatt, "Measurement of premorbid adjustment in chronic schizophrenia," *Schizophr. Bull.*, vol. 8, no. 3, pp. 470–484, 1982.
- [40] M. V. Seeman, "Gender differences in schizophrenia," *Can. J. Psychiatry*, vol. 27, no. 2, pp. 107–112, Mar. 1982.
- [41] K. M. Abel, R. Drake, and J. M. Goldstein, "Sex differences in schizophrenia," *Int. Rev. Psychiatry*, vol. 22, no. 5, pp. 417–428, 2010.
- [42] D. J. Castle and R. M. Murray, "The epidemiology of late-onset schizophrenia," *Schizophr. Bull.*, vol. 19, no. 4, pp. 691–700, 1993.
- [43] L. Nicole, A. Lesage, and P. Lalonde, "Lower incidence and increased male:female ratio in schizophrenia," *Br. J. Psychiatry*, vol. 161, pp. 556–557, Oct. 1992.

- [44] C. L. Barry, E. E. McGinty, B. A. Pescosolido, and H. H. Goldman, "Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness," *Psychiatr. Serv.*, vol. 65, no. 10, pp. 1269–1272, Oct. 2014.
- [45] P. W. Corrigan, S. A. Kuwabara, and J. O'Shaughnessy, "The Public Stigma of Mental Illness and Drug Addiction: Findings from a Stratified Random Sample," *J. Soc. Work*, vol. 9, no. 2, pp. 139–147, Apr. 2009.
- [46] P. Batel, "Addiction and schizophrenia," *Eur. Psychiatry*, vol. 15, no. 2, pp. 115–122, Mar. 2000.
- [47] P. Stefanatou, E. Giannouli, and P. Tsellos, "Metacognitive factors in a sample of Greek alcohol dependent patients," *European*, 2016.
- [48] E. E. McGinty, H. H. Goldman, B. Pescosolido, and C. L. Barry, "Portraying mental illness and drug addiction as treatable health conditions: effects of a randomized experiment on stigma and discrimination," *Soc. Sci. Med.*, vol. 126, pp. 73–85, Feb. 2015.
- [49] S. Potvin, E. Stip, and J.-Y. Roy, "Schizophrenia and addiction: An evaluation of the self-medication hypothesis," *Encephale*, vol. 29, no. 3 Pt 1, pp. 193–203, May 2003.
- [50] S. Mannarini and M. Boffo, "Anxiety, bulimia, drug and alcohol addiction, depression, and schizophrenia: what do you think about their aetiology, dangerousness, social distance, and treatment ...," *Soc. Psychiatry Psychiatr. Epidemiol.*, 2015.
- [51] D. Turkington, D. Kingdon, and T. Turner, "Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia," *Br. J. Psychiatry*, vol. 180, no. 6, pp. 523–527, Jun. 2002.
- [52] T. H. McGlashan and J. O. Johannessen, "Early detection and intervention with schizophrenia: rationale," *Schizophr. Bull.*, vol. 22, no. 2, pp. 201–222, 1996.
- [53] T. S. Stroup *et al.*, "The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development," *Schizophr. Bull.*, vol. 29, no. 1, pp. 15–31, 2003.
- [54] V. H. Chien and M. T. Compton, "The impact of mode of onset of psychosis on pathways to care in a hospitalized, predominantly African-American, first-episode sample," *Early Interv. Psychiatry*, vol. 2, no. 2, pp. 73–79, May 2008.
- [55] M. T. Compton, M. L. Esterberg, B. G. Druss, E. F. Walker, and N. J. Kaslow, "A descriptive study of pathways to care among hospitalized urban African American first-episode schizophrenia-spectrum patients," *Soc. Psychiatry Psychiatr. Epidemiol.*, vol. 41, no. 7, pp. 566–573, Jul. 2006.